Drug Considered (Generic)			roved	Rationale (additional details available upon request)
Paroxetine	3/5/2004, 05/01/2015		N	Risk of liver failure
Nefazodone	8/5/2004, 05/01/2015		N	ADR profile: Liver toxicity.
Pemoline	8/5/2004		N	Withdrawn from market
Thioridazine	8/5/2004		N	ADR profile: EKG changes - QT prolongation.
elbamate	10/8/2004		N N	No indication for use as a psychotropic medication in children.
Fiagabine	10/8/2004, 05/01/2015 4/1/2005		N N	Lack of data re safety and efficacy in children for psychiatric indications.
Herbals/Nutritional Suppl	12/1/2006		N N	Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product. Lack of data re efficacy in children for psychiatric indications.
Oxcarbazepine Foniromoto	12/1/2006		N N	Lack of data re efficacy in children for psychiatric indications. Lack of data re efficacy in children for psychiatric indications.
Topiramate Pimozide	9/5/2008		N	Lack or data re emicacy in children for psychiatric indications. ADR profile: EKG changes - OT protogation.
Atenolol	9/4/2009		N	ADD profile. EVE to tranges - 4th prototigation. Removed due to lack of safety data and experience with use in children and adolescents.
Vetoprolol	9/4/2009		N N	Removed due to lack of safety data and experience with use in children and addescents. Removed due to lack of safety data and experience with use in children and addescents.
Ramelteon	9/4/2009		N	Lack of safety-efficacy data in children. Data may be available Feb 2010.
Guanfacine XR	10/9/2009		N	Lativ to safety entracty data in climiteri. Data may be available red 2010. Pending further data once drug is actually available.
Ioperidone	3/5/2010		N	Lack of safety-efficacy data in children. Clinical trials not impressive. Need for careful titration is a concern. QTC interval is a concern.
Duloxetine	5/7/2010		N	Colly 1 Lilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data in College. Only 1 Lilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available.
Frazodone XR	8/6/2010		N	No advantage over trazodone IR when used for insommnia.
Molindone	11/5/2010		N	No longer available on the market.
Vadolol	1/7/2011		N	Removed due to lack indication for use in children and adolescents.
/erapamil	1/7/2011		N	Removed due to lack indication for use in children and adolescents
/ilazodone	10/5/2012		N	Pending results of clinical trials underway iinvolving children/adolescents.
Melatonin	1/6/06, 5/5/06, 1/6/08		N	Not under perview of PMAC: not an FDA regulated medication/possible inconsistency in formulations of the same product.
Asenapine	3/5/2010 & 5/6/2011		N	No safety-efficacy data for children available. Clinical trials not impressive. Concern over SL-buccal dosage form.
_urasidone	5/6/2011 & 10/5/2012		N	On market for <1yr. No data regarding use in children or adolescents. Must be given with 300cal meal. May increase prolactin levels.
Duloxetine	5/7/2010 & 10/5/2012, 05/01/2015		Υ	Restricted to: GAD, Ages 7-17
Molindone	12/4/2009		Y	Associated with weight loss vs. gain. To remain on the approved drug list.
Guanfacine XR	2/5/2010		Y	Safety and efficacy data now available. Reviewed and approved.
Olanzapine	2/5/2010		Y	On approved list but restricted to DCF MD review. Based on FDA required change in prescribing information relating to weight gain.
_amotrigine XR	8/6/2010		Y	But with a warning for use in children <13yrs old dure to lack of evidence for safety and efficacy in this age group.
Venlafaxine	3/5/2004 & 5/6/2011		Y	Higher risk of suicide per FDA advisory. New Study shows acceptable safety and efficacy.
Prazosin	6/5/2009 & 2/1/13		Υ	Approved with age based max dosing
Paliperidone	9/4/2009 & 5/6/2011		Y	Lack of safety-efficacy data in children. Now has FDA approval for use in children.
Methylphenidate ER liquid	4/5/2013		Y	Similar to other methylphenidate products already approved.
Oxcarbazepine	5/1/2009, 5/7/2010, 12/06/2013, 5/1/2015		N	Lack of safety-efficacy data in children. No new data available since last review.
Aripiprazole long acting irj	4/4/2014		N	Lack of safety and efficacy data in children and adolescents.
luphenazine decanoate	4/4/2014		Y	Only for children >=13yrs old.
Haloperidol decanoate	4/4/2014		Υ	Only for children >=13yrs old.
Nanzanina long acting ini	4/4/2014		N	Lack of safety and efficacy data in children and adolescents.
	4/4/2014		N	Lack of safety and efficacy data in children and adolescents.
Paliperidone long acting inj				
Paliperidone long acting inj Risperidone long acting inj	4/4/2014		Y	Only for children >=13yrs old.
Olanzapine long acting inj Paliperidone long acting inj Risperidone long acting inj Zaleplon	4/4/2014 5/1/2015		N	Removed due to lack of data regarding use in children/adolescents.
Paliperidone long acting inj Risperidone long acting inj	4/4/2014			
Paliperidone long acting inj Risperidone long acting inj Zaleplon Zolpidem	4/4/2014 5/1/2015 5/1/2015		N N	Removed due to lack of data regarding use in children/adolescents. Removed: study of 201 children showed no efficacy and significant adverse drug reactions.
Paliperidone long acting inj Risperidone long acting inj Zaleplon Zolpidem Drug Considered (Brand)	4/4/2014 5/1/2015 5/1/2015 Date of Review	Appı	N N roved	Removed due to lack of data regarding use in children/adolescents. Removed: study of 201 children showed no efficacy and significant adverse drug reactions. Rationale (additional details available upon request)
Paliperidone long acting inj Risperidone long acting inj Zaleplon Zolpidem Drug Considered (Brand) Paxil	4/4/2014 5/1/2015 5/1/2015 Date of Review 3/5/2004, 05/01/2015	Аррі	N N r oved N	Removed due to lack of data regarding use in children/adolescents. Removed: study of 201 children showed no efficacy and significant adverse drug reactions. Rationale (additional details available upon request) Risk of liver failure
Paliperidone long acting inj Risperidone long acting inj Zaleplon Zolpidem Drug Considered (Brand) Paxil	4/4/2014 5/1/2015 5/1/2015 Date of Review 3/5/2004, 05/01/2015 8/5/2004	Appi	N N roved N	Removed due to lack of data regarding use in children/adolescents. Removed: study of 201 children showed no efficacy and significant adverse drug reactions. Rationale (additional details available upon request) Risk of liver failure Withdrawn from market
Paliperidone long acting inj Risperidone long acting inj Zaleplon Zolpidem Drug Considered (Brand) Paxil Cylert	4/4/2014 5/1/2015 5/1/2015 Date of Review 3/5/2004, 05/01/2015 8/5/2004	Appı	N N roved N N	Removed due to lack of data regarding use in children/adolescents. Removed: study of 201 children showed no efficacy and significant adverse drug reactions. Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profile: EKG changes - OT prolongation.
Paliperidone long acting inj Risperidone long acting inj Paleplon Colpidem Parug Considered (Brand) Paruj Paruj Vylert Hellaril Berzone	4/4/2014 5/1/2015 5/1/2015 Date of Review 3/5/2004, 05/01/2015 8/5/2004 8/5/2004 8/5/2004	Appi	N N N roved N N N	Removed due to lack of data regarding use in children/adolescents. Removed: study of 201 children showed no efficacy and significant adverse drug reactions. Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profile: EKG changes - QT prolongation. ADR profile: EVEV toxicity.
Paliperidone long acting inj Risperidone long acting inj Zaleplon Zaleplon Drug Considered (Brand) Paxil Dylert Mellaril Serzone Felbatol	4/4/2014 5/1/2015 5/1/2015 Date of Review 3/5/2004, 05/01/2015 8/5/2004 8/5/2004 8/5/2004 8/5/2004 10/6/2004	Appı	roved N N N N N N	Removed: study of 201 children showed no efficacy and significant adverse drug reactions. Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profile: EVer footing: ADR profile: EVer footing: No indication for use as a psychotropic medication in children.
Paliperidone long acting inj Risperidone long acting inj Zalepilon Copipidem Drug Considered (Brand) axil Vylert Hellaril Berzone Felbatol Sabitril	4/4/2014 5/1/2015 5/1/2015 Date of Review 3/5/2004, 05/01/2015 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 10/8/2004 10/8/2004 10/8/2004, 05/01/2015	Appı	roved N N N N N N N	Removed due to lack of data regarding use in children/adolescents. Removed: study of 201 children showed no efficacy and significant adverse drug reactions. Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profile: EKG changes - OT prolongation. ADR profile: Lever toxicity. No indication for use as a psychotropic medication in children. Lack of data re sately and efficacy in children for psychiatric indications.
Paliperidone long acting inj Skperidone long acting inj Zaleplon Drug Considered (Brand) Paxil Dylert Wellaril Serzone Felbatol Sabitril Suppl	4/4/2014 5/1/2015 Date of Review 3/6/2004 5/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2005	Appı	roved N N N N N N N	Removed: study of 201 children showed no efficacy and significant adverse drug reactions. Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profile: EKG changes - OT prolongation. ADR profile: EKG changes - OT prolongation. ADR profile: Liver toxicity. No indication for use as a psychotropic medication in children. Lack of data re safety and efficacy in children for psychiatric indications. Not under perview of PMAC as they are not FDR A regulated medications/possible inconsistency in formulations of the same product.
Paliperidone long acting inj Risperidone long acting inj Zaleplon Drug Considered (Brand) axil Vylert Wellarii Serzone Felbatol Sabirii Herbals/Nutritional Suppl Topamax	4/4/2014 5/11/2015 5/11/2015 Date of Review 3/5/2004, 05/01/2015 8/5/2004 8/5/2004 8/5/2004 8/5/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2005 11/1/2005 12/11/2006, 05/01/2015	Appı	roved N N N N N N N N N N	Removed due to lack of data regarding use in children/adolescents. Removed: study of 201 children showed no efficacy and significant adverse drug reactions. Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profile: EKG changes - OT prolongation. ADR profile: EVI troticity. No indication for use as a psychotropic medication in children. Lack of data re safety and efficacy in children for psychiatric indications. Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product. Lack of data re efficacy in children for psychiatric indications.
Paliperidone long acting inj Risperidone long acting inj Zaleplon Drug Considered (Brand) Paxil Dylert Wellarii Serzone Flebatol Jabitrii Salbitrii Salbitrii Flopamax Trileptat	4/4/2014 5/1/2015 Date of Review 3/6/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2005 12/1/2006 12/1/2006 12/1/2006	Appı	roved N N N N N N N N N N	Removed: study of 201 children showed no efficacy and significant adverse drug reactions. Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profile: EKG changes - QT prolongation. ADR profile: EKG changes - QT prolongation. ADR profile: Liver toxicity. ADR details available upon request of the state of the st
Paliperidone long acting inj Risperidone long acting inj Zalepilon Drug Considered (Brand) axil Drug Considered (Brand) Experimental Serzone Felbatol Sabiril Ferbals/Nutritional Suppl Topamax Trileptal Topa	4/4/2014 5/11/2015 5/11/2015 Date of Review 3/6/2004, 05/01/2015 8/6/2004 8/6/2004 8/6/2004 8/6/2004 8/6/2004 6/6/2004 6/6/2004 6/6/2005 1/11/2006 6/6/2006 9/6/2008	Appı	N N N N N N N N N N N N	Removed due to lack of data regarding use in children/adolescents. Removed: study of 201 children showed no efficacy and significant adverse drug reactions. Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profile: EKG changes - OT prolongation. ADR profile: EVI to toxicity. No indication for use as a psychotropic medication in children. Lack of data re safety and efficacy in children for psychiatric indications. Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product. Lack of data re efficacy in children for psychiatric indications. Lack of data re efficacy in children for psychiatric indications. Lack of data re efficacy in children for psychiatric indications. ADR profile: EKG changes - OT prolongation.
Paliperidone long acting inj Risperidone long acting inj Zaleplon Drug Considered (Brand) Paxil Dylert Vellarii Serzone	4/4/2014 5/1/2015 Date of Review 3/5/2004 5/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2009 12/1/2006 9/5/2008 9/4/2009	Appi	N N N N N N N N N N N N N N N N N N N	Removed: study of 201 children showed no efficacy and significant adverse drug reactions. Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profile: EKG changes - OT prolongation. ADR profile: EKG changes - OT prolongation. ADR profile: Liver toxicity. No indication for use as a psychotropic medication in children. Lack of data re safety and efficacy in children for psychiatric indications. Not under perview of PMAC as they aren or FDR regulated medications/possible inconsistency in formulations of the same product. Lack of data re efficacy in children for psychiatric indications. Lack of data re efficacy in children for psychiatric indications. Lack of data re efficacy in children for psychiatric indications. ADR profile: EKG changes - OT prolongation. Removed due to lack of safety data and experience with use in children and adolescents.
Paliperidone long acting inj Risperidone long acting inj Zalepilon Drug Considered (Brand) axil Drug Considered (Brand) axil Vylert Mellaril Serzone Felbatol Sabiril Ferbals/Nutritional Suppl Topamax Trileptal Drap Opressor Rozerem	4/4/2014 5/11/2015 5/11/2015 Date of Review 3/6/2004, 05/01/2015 8/6/2004 8/6/2004 8/6/2004 8/6/2004 8/6/2004 8/6/2004 6/6/2004 6/6/2005 12/1/2006 12/1/2006 9/6/2008 9/4/2009 9/4/2009	Appi	roved N N N N N N N N N N N N N N N N N N N	Removed due to lack of data regarding use in children/adolescents. Removed: study of 201 children showed no efficacy and significant adverse drug reactions. Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profile: EKG changes - OT protongation. ADR profile: Liver troxicity. No indication for use as a psychotropic medication in children. Lack of data re safety and efficacy in children for psychiatric indications. Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product. Lack of data re efficacy in children for psychiatric indications. Lack of data re efficacy in children for psychiatric indications. ADR profile: EKG changes - OT protongation. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety additional duried.
Paliperidone long acting inj Istoperidone long acting inj Zaleplon Drug Considered (Brand) Paxil Paxil Evitable Serzone Flebatol Sabitril Opamax Trileptal Drap Oppressor Rozerem Fenormin	4/4/2014 5/1/2015 Date of Review 3/5/2004 5/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2009 12/1/2006 9/5/2008 9/4/2009 9/4/2009 9/4/2009	Appi	N N N N N N N N N N N N N N N N N N N	Removed due to lack of data regarding use in children/adolescents. Removed: study of 201 children showed no efficacy and significant adverse drug reactions. Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profile: EKG changes - QT prolongation. ADR profile: EKG changes - QT prolongation. ADR profile: Liver toxicity. No indication for use as a psychotropic medication in children. Lack of data re safety and efficacy in children for psychiatric indications. Not under perview of PMAC as they aren or EDR regulated medications/possible inconsistency in formulations of the same product. Lack of data re efficacy in children for psychiatric indications. Lack of data re efficacy in children for psychiatric indications. ADR profile: EKG changes - QT prolongation. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available Feb 2010. Removed due to lack of safety data and experience with use in children and adolescents.
Paliperdone long acting inj Risperidone long acting inj Zalepion Drug Considered (Brand) axi Drug Considered (Brand) axi Vylert Mellarii Serzone Felbatol Sabirii Ferbals/Nutritional Suppl Topamax Trileptal Drap Opressor Rozerem Fenormin Huniv	4/4/2014 4/4/2014 5/11/2015 5/11/2015 Date of Review 3/6/2004, 05/01/2015 8/6/2004 8/6/2004 8/6/2004 8/6/2004 8/6/2004 6/6/2004 6/6/2005 1/11/2006 6/6/2006 9/6/2009 9/4/2009 9/4/2009 1/0/9/2009	Appi	N N N N N N N N N N N N N N N N N N N	Removed: study of 201 children showed no efficacy and significant adverse drug reactions. Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profile: EKG changes - OT protongation. ADR profile: Liver troxicity. No indication for use as a psychotropic medication in children. Lack of data re safety and efficacy in children for psychiatric indications. Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product. Lack of data re efficacy in children for psychiatric indications. ADR profile: EKG changes - OT protongation. ADR profile: EKG changes - OT protongation. Removed due to lack of safety add efficacy in children for psychiatric indications. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety additional describacy and a subject of the same product. Removed due to lack of safety data and experience with use in children and adolescents. Removed due to lack of safety data and experience with use in children and adolescents. Pending further data nonce drug is actually available feb 2010. Removed due to lack of safety data and experience with use in children and adolescents.
Paliperidone long acting inj Istoperidone long acting inj Istoperidone long acting inj Istoperidone long acting inj Istoperidone Istope	4/4/2014 5/1/2015 Date of Review 3/5/2004 5/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2009 12/1/2006 9/5/2008 9/4/2009 9/4/2009 10/9/2009 3/5/2001	Appi	N N N N N N N N N N N N N N N N N N N	Removed due to lack of data regarding use in children/adolescents. Removed: study of 201 children showed no efficacy and significant adverse drug reactions. Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profile: EKG changes - QT prolongation. ADR profile: EKG changes - QT prolongation. ADR profile: Liver toxicity. No indication for use as a psychotropic medication in children. Lack of data re safety and efficacy in children for psychiatric indications. Not under perview of PMAC as they are not PDA regulated medications/possible inconsistency in formulations of the same product. Lack of data re efficacy in children for psychiatric indications. Lack of data re efficacy in children for psychiatric indications. Lack of data re efficacy in children for psychiatric indications. ADR profile: EKG changes - QT prolongation. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available Feb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available reported the profile of the profile
Paliperidone long acting inj Isteperidone Ist	4/4/2014 5/11/2015 5/11/2015 Date of Review 3/5/2004, 05/01/2015 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 10/8/2004 10/8/2004 10/8/2005 12/1/2005 12/1/2006 9/5/2008 9/4/2009 9/4/2009 9/4/2009 9/4/2009 10/9/2009 3/5/2010 5/7/2010	Appr	N N N N N N N N N N N N N N N N N N N	Removed: study of 201 children showed no efficacy and significant adverse drug reactions. Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profile: EKG changes - OT prolongation. ADR profile: Liver troicity. No indication for use as a psychotropic medication in children. Lack of data re safety and efficacy in children for psychiatric indications. Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product. Lack of data re efficacy in children for psychiatric indications. ADR profile: EKG changes - OT prolongation. ADR profile: EKG changes - OT prolongation. ADR profile: EKG changes - OT prolongation. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety and efficacy in children. Data may be available Feb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Pending further data once drug is actually available. Lack of safety-efficacy data in children. Data may be available feb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available feb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available feb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available. Lack of safety-efficacy data in children. Data may be available in penetre. Deven provoqual until efficacy data is available.
Paliperidone long acting inj itsperidone long acting inj zalepion Prug Considered (Brand) Paxil Pyert dellaria	4/4/2014 5/1/2015 Date of Review 3/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2009 12/1/2006 9/4/2009 9/4/2009 10/9/2009 10/9/2009 15/7/2010 8/6/2010	Appr	roved N N N N N N N N N N N N N N N N N N N	Removed due to lack of data regarding use in children/adolescents. Removed: study of 201 children showed no efficacy and significant adverse drug reactions. Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profile: EKG changes - QT prolongation. ADR profile: EKG changes - QT prolongation. ADR profile: Liver toxicity. No indication for use as a psychotropic medication in children. Lack of data re safety and efficacy in children for psychiatric indications. Not under perview of PMAC as they are not PDA regulated medications/possible inconsistency in formulations of the same product. Lack of data re efficacy in children for psychiatric indications. Lack of data re efficacy in children for psychiatric indications. Lack of data re efficacy in children for psychiatric indications. ADR profile: EKG changes - QT prolongation. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available Feb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available feb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Chilical trials not impressive. Need for careful titration is a concern. QTC interval is a concern. Only 1 Lilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available.
Paliperidone long acting inj Isteperidone Ist	4/4/2014 5/11/2015 5/11/2015 Date of Review 3/5/2004, 05/01/2015 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2005 12/11/2006 9/5/2008 9/4/2009 9/4/2009 9/4/2009 9/4/2009 9/4/2009 10/9/2009 3/5/2010 5/7/2010 8/6/2010 11/5/2010	Appi	N N N N N N N N N N N N N N N N N N N	Removed due to lack of data regarding use in children/adolescents. Rationale (additional details available upon request) Risk of liver failure Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profile: EKG changes - OT protongation. ADR profile: Liver toxicity. No indication for use as a psychotropic medication in children. Lack of data re safety and efficacy in children for psychiatric indications. Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product. Lack of data re efficacy in children for psychiatric indications. ADR profile: EKG changes - OT protongation. ADR profile: EKG changes - OT protongation. Removed due to lack of safety add attain and sepretence with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available Feb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available Feb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available Feb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available reb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available reb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available reb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Lock of safety-efficacy data in children. Data may be available reb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Lock of safety-efficacy data in children. Data may b
Paliperidone long acting inj itsperidone Portug Considered (Brand) Pakil Poyert Poyert Political Poyert Political Poparax Tripetat Prap Doperssor Rozerem Fenormin Intuniv anapt Joymbatta Deptro Johan Joha	4/4/2014 5/1/2015 Date of Review 3/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2009 9/4/2009 9/4/2009 9/4/2009 10/9/2009 10/9/2009 11/5/2010 11/5/2010 11/5/2010 11/5/2010	Appi	roved N N N N N N N N N N N N N N N N N N	Removed due to lack of data regarding use in children/adolescents. Removed: study of 201 children showed no efficacy and significant adverse drug reactions. Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profile: EKG changes - QT prolongation. ADR profile: EKG changes - QT prolongation. ADR profile: Liver toxicity. No indication for use as a psychotropic medication in children. Lack of data re safety and efficacy in children for psychiatric indications. Not under perview of PMAC as they are not PDA regulated medications/possible inconsistency in formulations of the same product. Lack of data re efficacy in children for psychiatric indications. Lack of data re efficacy in children for psychiatric indications. Lack of data re efficacy of the children for psychiatric indications. ADR profile: EKG changes - QT prolongation. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available Feb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available for particular data of the prefine with use in children and adolescents. Lack of safety-efficacy data in children. Clinical trials not impressive. Need for careful titration is a concern. QTC interval is a concern. Only 1 Lilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available. No longer available on the market.
Paliperidone long acting inj Isteperidone Ist	4/4/2014 4/4/2014 5/11/2015 5/11/2015 Date of Review 3/5/2004, 05/01/2015 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 10/8/2004 10/8/2004 10/8/2005 12/1/2006 9/5/2008 9/4/2009 9/4/2009 9/4/2009 9/4/2009 9/4/2009 9/4/2009 10/9/2009 3/5/2010 5/7/2010 8/6/2010 11/5/2010 11/5/2011 11/7/2011	Appr	N N N N N N N N N N N N N N N N N N N	Removed due to lack of data regarding use in children/adolescents. Removed: study of 201 children showed no efficacy and significant adverse drug reactions. Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profile: EKG changes - OT protongation. ADR profile: Liver troxicity. No indication for use as a psychotropic medication in children. Lack of data re safety and efficacy in children for psychiatric indications. Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product. Lack of data re efficacy in children for psychiatric indications. ADR profile: EKG changes - OT protongation. ADR profile: EKG changes - OT protongation. Removed due to lack of safety add stand and sepretence with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available Feb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available Feb 2010. Removed due to lack of safety data in children. Latina may be available feb 2010. Removed due to lack of safety may be available feb 2010. Removed due to lack of safety data in children. Data may latinable. Lack of safety-efficacy data in children. Data may latinable. No advantage over trazodone IR when used for insommnia. No longer available on the market. Removed due to lack indication for use in children and adolescents.
Paliperidone long acting inj itsperidone long acting inj zaleplon Prug Considered (Brand) Paxil Paylert dellarii erzone dellarii sabitrii paparax Trieptal Prap parp Trieptal Prap Trieptal Triept	4/4/2014 5/1/2015 Date of Review 3/5/2004 5/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2009 11/1/2006 9/4/2009 9/4/2009 10/9/2009 10/9/2009 11/5/2010 11/5/2010 11/5/2010 11/5/2010 11/5/2011 11/5/2011	Appi	N N N roved N N N N N N N N N N N N N N N N N N N	Removed due to lack of data regarding use in children/adolescents. Removed: study of 201 children showed no efficacy and significant adverse drug reactions. Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profile: EKS changes - QT prolongation. ADR profile: EKS changes - QT prolongation. ADR profile: Liver toxicity. No indication for use as a psychotropic medication in children. Lack of data re safety and efficacy in children for psychiatric indications. Not under perview of PMAC as they are not PDA regulated medications/possible inconsistency in formulations of the same product. Lack of data re efficacy in children for psychiatric indications. Lack of data re efficacy in children for psychiatric indications. Lack of data re efficacy of the children for psychiatric indications. Lack of data re efficacy of the children for psychiatric indications. Lack of safety-efficacy data in children. Data may be available Feb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Chilcal trials not impressive. Need for careful titration is a concern. QTC interval is a concern. Only 1 Lilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available. No longer available on the market. Removed due to lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents.
Paliperidone long acting inj Istoperidone long acting inj Istoperidone long acting inj Istoperidone long acting inj Istoperidone Istope	4/4/2014 4/4/2014 5/11/2015 5/11/2015 Date of Review 3/5/2004, 05/01/2015 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 10/8/2004 10/8/2004 10/8/2005 12/1/2005 12/1/2006 9/5/2008 9/4/2009 9/4/2009 9/4/2009 9/4/2009 9/4/2009 10/9/2009 3/5/2010 5/7/2010 8/6/2010 11/5/2010 11/5/2011 1/7/2011 1/7/2011 1/7/2011 1/7/2011 1/5/2010	Appr	N N N N N N N N N N N N N N N N N N N	Removed due to lack of data regarding use in children/adolescents. Removed: study of 201 children showed no efficacy and significant adverse drug reactions. Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profile: EKG changes - OT protongation. ADR profile: Liver troxicity. No indication for use as a psychotropic medication in children. Lack of data re stelly and efficacy on children for psychiatric indications. Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product. Lack of data re efficacy in children for psychiatric indications. ADR profile: EKG changes - OT protongation. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available Feb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available feb 2010. Removed due to lack of safety data in children. The control of the same product. Lack of safety-efficacy data in children. Data may be available feb 2010. No advantage over trazodone IR when used for insommnia. No longer available on the market. Removed due to lack indication for use in children and adolescents. Pending further loak indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Pending results of lack indication for use in children and adolescents. Pending results of children of a reformation and provided to the same product.
Paliperidone long acting inj itsperidone long acting inj itsperidone long acting inj zaleplon Prug Considered (Brand) Paxil Payler Helbari Herbals Hurri Herbals Hopamax Trileptal Prap Jorgesor Hozerem Henormin Hurniv Harapt Jorgesor Horbari Herbari Helbari Helb	4/4/2014 5/1/2015 Date of Review 3/5/2004 5/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2009 11/1/2006 9/4/2009 9/4/2009 10/9/2009 10/9/2009 11/5/2010 11/5/2010 11/5/2010 11/5/2010 11/5/2011 11/5/2011	Appr	N N N N N N N N N N N N N N N N N N N	Removed due to lack of data regarding use in children/adolescents. Removed: study of 201 children showed no efficacy and significant adverse drug reactions. Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profile: EKS changes - QT prolongation. ADR profile: EKS changes - QT prolongation. ADR profile: Liver toxicity. No indication for use as a psychotropic medication in children. Lack of data re safety and efficacy in children for psychiatric indications. Not under perview of PMAC as they are not PDR regulated medications/possible inconsistency in formulations of the same product. Lack of data re efficacy in children for psychiatric indications. Lack of data re efficacy in children for psychiatric indications. Lack of data re efficacy of the children for psychiatric indications. ADR profile: EKG changes - QT prolongation. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available Feb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Pending further data once drug is actually available. Lack of safety-efficacy data in children. Clinical trials not impressive. Need for careful titration is a concern. QTC interval is a concern. Only 1 Lilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available. No longer available on the market. Removed due to lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Not under perview of PMAC: not an FDA regulated medication/possible inconsistency in formulations of the same product. No
Paliperidone long acting inj Isteperidone Ist	4/4/2014 5/11/2015 5/11/2015 Date of Review 3/5/2004, 05/01/2015 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2005 10/8/2005 12/1/2006 9/5/2008 9/4/2009 9/4/2009 9/4/2009 9/4/2009 9/4/2009 10/9/2009 3/5/2010 5/7/2010 8/6/2010 11/5/2010 11/7/2011	Appr	N N N N N N N N N N N N N N N N N N N	Removed due to lack of data regarding use in children/adolescents. Rationale (additional details available upon request) Risk of liver failure Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profile: EKG changes - OT protongation. ADR profile: EVE to xicity. No indication for use as a psychotropic medication in children. Lack of data re safety and efficacy in children for psychiatric indications. Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product. Lack of data re efficacy in children for psychiatric indications. ADR profile: EKG changes - OT protongation. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available Feb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available feb 2010. Removed due to lack of safety data in children. Total may be available feb 2010. Removed due to lack of safety data in children. Data may lack under the safety of the same product. No advantage over trazodone IR when used for insommaia. No longer available on the market. Removed due to lack indication for use in children and adolescents. Pending results of lack and calculation and adolescents. Removed due to lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Pending results of children available. Clinical trials not impressive. Oncern over St-buccal dosage form. No safety-efficacy data for children available. Clinical trials not impressive. Oncern over St-buccal dosage form.
Paliperidone long acting inj itsperidone long acting inj zaleplon Prug Considered (Brand) Paxil Payler Helbari Helba	4/4/2014 5/1/2015 Date of Review 3/5/2004 5/5/2015 B15/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2009 12/1/2006 9/4/2009 9/4/2009 9/4/2009 9/4/2009 10/9/2009 3/5/2010 5/7/2010 8/6/2010 11/5/2010 11/7/2011 11/7/2011 10/5/2012 1/8/06, 5/5/06, 1/6/08	Appl	N N N N N N N N N N N N N N N N N N N	Removed due to lack of data regarding use in children/adolescents. Removed: study of 201 children showed no efficacy and significant adverse drug reactions. Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profile: EKS changes - QT prolongation. ADR profile: EKS changes - QT prolongation. ADR profile: Liver toxicity. No indication for use as a psychotropic medication in children. Lack of data re safety and efficacy in children for psychiatric indications. Not under perview of PMAC as they are not PDR regulated medications/possible inconsistency in formulations of the same product. Lack of data re efficacy in children for psychiatric indications. Lack of data re efficacy in children for psychiatric indications. Lack of data re efficacy of the children for psychiatric indications. ADR profile: EKG changes - QT prolongation. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available Feb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Pending further data once drug is actually available. Lack of safety-efficacy data in children. Clinical trials not impressive. Need for careful titration is a concern. QTC interval is a concern. Only 1 Lilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available. No longer available on the market. Removed due to lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Not under perview of PMAC: not an FDA regulated medication/possible inconsistency in formulations of the same product. No
Paliperidone long acting inj Istoperidone long acting inj Istoperidone long acting inj Istoperidone long acting inj Istoperidone Istope	4/4/2014 5/1/2015 Date of Review 3/5/2004, 05/01/2015 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2009 9/4/2009 9/4/2009 9/4/2009 9/4/2009 10/9/2009 3/5/2010 5/7/2010 8/6/2010 11/5/2011 11/7/2011 11/7/2011 11/5/2012 11/8/06, 5/5/06, 1/6/08 3/5/2010 & 5/6/2011 5/6/2011 & 1/6/2011 5/6/2011 & 1/6/2011	Appr	N N N POVED	Removed due to lack of data regarding use in children/adolescents. Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profiles EKS changes - QT prolongation. Lack of data re safety and efficacy in children for psychiatric indications. Lack of data re efficacy in children for psychiatric indications. Lack of data re efficacy or children for psychiatric indications. Lack of data re efficacy or children for psychiatric indications. Lack of data re efficacy or children for psychiatric indications. Lack of data re efficacy or children for psychiatric indications. Lack of safety-efficacy data in children. Data may be available Feb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available Feb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Pending further data once drug is actually available. Lack of safety-efficacy data in children. Clinical trials not impressive. Need for careful titration is a concern. QTC interval is a concern. Only 1 Lilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available. No longer available on the market. Removed due to lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Removed
Paliperidone long acting inj Istiperidone long acting inj Isteperidone long acting inj Isteperidone long acting inj Isteperidone long acting inj Istiperidone long acting inj Istiperidone	4/4/2014 5/11/2015 5/11/2015 Date of Review 3/5/2004, 05/01/2015 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2005 10/8/2005 12/1/2006 9/5/2008 9/4/2009 9/4/2009 9/4/2009 9/4/2009 9/4/2009 9/4/2009 9/4/2009 10/9/2009 3/5/2010 5/7/2010 8/6/2010 11/5/2011 11/7/2011 11/5/2011 1/7/2011 1/5/2012 1/5/06, 5/5/06, 1/6/08 3/5/2010 & 8/6/2011 5/5/2011 & 1/5/2012 5/7/2010 & 1/5/2012 5/7/2010 & 1/5/2012 5/7/2010 & 1/5/2012	Appi	N N roved N N N N N N N N N N N N N N N N N N N	Removed: study of 201 children showed no efficacy and significant adverse drug reactions. Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profile: EKG changes - OT prolongation. ADR profile: Liver tracity. No indication for use as a psychotropic medication in children. Lack of data re stelly and efficacy or in children for psychiatric indications. Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product. Lack of data re efficacy in children for psychiatric indications. ADR profile: EKG changes - OT prolongation. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available Feb 2010. Removed due to lack of safety data in children. Indications use in children and adolescents. Pending further data once drug is actually available. Lack of safety-efficacy data in children. Data may be available Feb 2010. No advantage over trazodone IR when used for insommnia. No longer available on the market. Removed due to lack indication for use in children and adolescents. Pending results of lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Pending results of children and an adolescents. Pending results of children and adolescents. Pending results of children available. Clinical trials not impressive. Ocnoem over St. buccal dosage form. On market for A. The Repulated medication/possible inconsistency in formulations of the same product. No safety-efficacy data for children available. Clinical trials
Paliperidone long acting inj Istiperidone long acting inj Isteperidone long acting inj Isteperidone long acting inj Isteperidone long acting inj Istiperidone long acting inj Istiperidone	4/4/2014 5/1/2015 Date of Review 3/5/2004, 05/01/2015 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2006 12/1/2006 9/4/2009 9/4/2009 9/4/2009 10/9/2009 10/9/2009 11/5/2010 11/5/2011 11/7/2011 11/7/2011 11/7/2011 11/5/2012 11/6/06, 5/5/06, 1/6/08 3/5/2010 & 5/6/2011 5/6/2011 & 10/5/2012 5/7/2010 & 10/5/2012 11/6/06, 5/5/06, 1/6/00 3/5/2010 11/5/2011 11/5/2011 11/5/2011 11/5/2011 11/5/2011 11/5/2011 11/5/2010	Appr	N N N N N N N N N N N N N N N N N N N	Removed due to lack of data regarding use in children/adolescents. Rationale (additional details available upon request) Risk of liver failure Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profile: EKG changes - QT prolongation. ADR profile: EVG changes - QT prolongation. ADR profile: EVG changes - QT prolongation. ADR profile: EVG changes - QT prolongation. Lock of data re selfty and efficacy or in children for psychiatric indications. Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product. Lock of data re efficacy in children for psychiatric indications. Lock of data re efficacy in children for psychiatric indications. ADR profile: EKG changes - QT prolongation. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available feb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available feb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available feb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Ponding further data once drug is actually available in peptine. Deny approval until efficacy data is available. No advantage over trazodone it when used for insommina. No longer available on the marker. Removed due to lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Not under perview of PMAC: not an FDA requisted medication/possible inconsistency in formulations
Paliperdone long acting inj Istoperione long Istoperi	4/4/2014 5/11/2015 5/11/2015 Date of Review 3/5/2004, 05/01/2015 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2005 10/8/2005 12/1/2006 9/5/2008 9/4/2009 9/4/2009 9/4/2009 9/4/2009 9/4/2009 9/4/2009 9/4/2009 10/9/2009 3/5/2010 5/7/2010 8/6/2010 11/5/2011 11/7/2011 11/5/2011 1/7/2011 1/5/2012 1/5/06, 5/5/06, 1/6/08 3/5/2010 & 8/6/2011 5/5/2011 & 1/5/2012 5/7/2010 & 1/5/2012 5/7/2010 & 1/5/2012 5/7/2010 & 1/5/2012	Appr	N N TOVED N N N N N N N N N N N N N N N N N N N	Removed: study of 201 children showed no efficacy and significant adverse drug reactions. Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profile: EKG changes - OT prolongation. ADR profile: Liver tracity. No indication for use as a psychotropic medication in children. Lack of data re stelly and efficacy or in children for psychiatric indications. Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product. Lack of data re efficacy in children for psychiatric indications. ADR profile: EKG changes - OT prolongation. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available Feb 2010. Removed due to lack of safety data in children. Indications use in children and adolescents. Pending further data once drug is actually available. Lack of safety-efficacy data in children. Data may be available Feb 2010. No advantage over trazodone IR when used for insommnia. No longer available on the market. Removed due to lack indication for use in children and adolescents. Pending results of lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Pending results of children and an adolescents. Pending results of children and adolescents. Pending results of children available. Clinical trials not impressive. Ocnoem over St. buccal dosage form. On market for A. The Repulated medication/possible inconsistency in formulations of the same product. No safety-efficacy data for children available. Clinical trials
Paliperidone long acting inj Istiperidone long acting inj Isteperidone long acting inj Isteperidone long acting inj Isteperidone long acting inj Istiperidone long acting inj Istiperidone	4/4/2014 5/1/2015 Date of Review 3/5/2004, 05/01/2015 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 10/8/2004, 05/01/2015 10/8/2004 10/8/2004, 05/01/2015 10/8/2004 10/8/2004 10/8/2009 9/4/2009 9/4/2009 9/4/2009 9/4/2009 10/9/2009 3/5/2010 5/7/2010 8/6/2010 11/5/2011 11/7/2011 11/7/2011 11/7/2011 11/5/2012 11/8/06, 5/5/06, 1/6/08 3/5/2010 & 5/6/2011 5/6/2010 & 10/5/2012 5/7/2010 & 10/5/2012 11/8/06, 5/5/06, 1/6/09 3/5/2010 1/5/2011 10/5/2012 11/8/06, 5/5/06, 1/6/09 3/5/2010 1/5/2004 1/5/2004 1/5/2004 1/5/2004 1/5/2004 1/5/2004 1/5/2004 1/5/2004 1/5/2004 1/5/2008 1/5/2004 1/5/2004 1/5/2004 1/5/2004	Appr	N N N N N N N N N N N N N N N N N N N	Removed due to lack of data regarding use in children/adolescents. Rationale (additional details available upon request) Risk of liver failure Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profile: EKG changes - QT prolongation. ADR profile: EVG changes - QT prolongation. ADR profile: EVG changes - QT prolongation. ADR profile: EVG changes - QT prolongation. Lock of data re sidery and efficacy in children for psychiatric indications. Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product. Lack of data re efficacy in children for psychiatric indications. ADR profile: EKG changes - QT prolongation. Removed due to lack of safety add stand and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available feb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available feb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available feb 2010. Removed due to lack of safety data in children. Total may be available feb 2010. No advantage over trazcodone IR when used for insommnia. No longer available on the marker. Removed due to lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Remove
Paliperdone long acting inj Istoperione long Istoperi	4/4/2014 5/11/2015 5/11/2015 Date of Review 3/5/2004, 05/01/2015 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2005 10/8/2005 12/1/2006 9/5/2008 9/4/2009 9/4/2009 9/4/2009 9/4/2009 9/4/2009 10/9/2009 3/5/2010 5/7/2010 8/6/2010 11/5/2010 11/7/2011 10/5/2012 1/6/06, 5/5/06, 1/6/08 3/5/2010 & 8/6/2011 1/7/2011 1/7/2011 1/5/2012 1/6/06, 5/5/06, 1/6/08 3/5/2010 & 8/6/2011 5/7/2010 & 8/6/2011	Appr	N N TOVED N N N N N N N N N N N N N N N N N N N	Removed: study of 201 children showed no efficacy and significant adverse drug reactions. Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profile: EKG changes - OT protongation. ADR profile: Liver tracity. No indication for use as a psychotropic medication in children. Lack of data re stelly and efficacy in children for psychiatric indications. Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product. Lack of data re efficacy in children for psychiatric indications. ADR profile: EKG changes - OT protongation. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available Feb 2010. Removed due to lack of safety data in children. Data may be available feb 2010. Removed due to lack of safety data in children. Data may be available feb 2010. No advantage over trazodone IR when used for insommnia. No longer available on the market. Removed due to lack indication for use in children and adolescents. Pending results of childra fails underway involving children/adolescents. Pending results of childra fails underway involving children/adolescents. Pending results of children available. Clinical trials not impressive. Oncome over Stbuccal dosage form. On market for 4Vr. No data regarder and adolescents. Pending results of children available. Clinical trials not impressive. Oncome over Stbuccal dosage form. On market for 4Vr. No data regarding use in children or adolescents.
Paliperidone long acting inj istsperidone Porug Considered (Brand) axii Porug Considered (Brand) axii Porug Considered (Brand) axii Politore Perizone Ferzone	4/4/2014 5/1/2015 Date of Review 3/5/2004 05/01/2015 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2008 9/4/2009 9/4/2009 9/4/2009 9/4/2009 1/9/2009	Appi	N N N N N N N N N N N N N N N N N N N	Removed: study of 201 children showed no efficacy and significant adverse drug reactions. Rationale (additional details available upon request) Risk of liver failure Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profile: EKG changes - OT protongation. ADR profile: EVER changes - OT protongation. ADR profile: EVER changes - OT protongation. ADR profile: EVER of the viscity. No indication for use as a psychotropic medication in children. Lack of data re settly and efficacy or in children for psychiatric indications. Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product. Lack of data re efficacy in children for psychiatric indications. ADR profile: EKG changes - OT protongation. ADR profile: EKG changes - OT protongation. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available Feb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Pending further data once drug is actually available. Lack of safety-efficacy data in children. Data may be available Feb 2010. Removed due to lack of safety data in children. Data may be available Feb 2010. No advantage over trazodone IR when used for insommnia. No longer available on the market. Removed due to lack indication for use in children and adolescents. Pending results of lack and in children. Data may in the provision of the same product. No safety-efficacy data in children. Data may consider the provision of the same product. No longer available on the market. Removed due to lack indication for use in children and adolescents. Pending results of clinical trials underway involving children/adolescents. Pending results of clinical trials underway involving children/adolescents. Pending results of clinical trials underway involving children/adolescents. Pending results of clinical tr
Paliperidone long acting inj istsperidone long istsperidone istsperi	4/4/2014 5/1/2015 Date of Review 3/5/2004 05/01/2015 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2008 9/4/2009 9/4/2009 9/4/2009 9/4/2009 1/9/2009	Appi	N N O O O O O O O O O O O O O O O O O O	Removed due to lack of data regarding use in children/adolescents. Rationale (additional details available upon request) Risk of liver failure Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profile: EKG changes - QT prolongation. ADR profile: EVG changes - QT prolongation. ADR profile: EVG changes - QT prolongation. Lock of data re settley and efficacy in children for psychiatric indications. Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product. Lack of data re efficacy in children for psychiatric indications. ADR profile: EKG changes - QT prolongation. ADR profile: EKG changes - QT prolongation. Removed due to lack of safety add state and experience with use in children and adolescents. Lack of safety efficacy data in children. Data may be available feb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available feb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available feb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available. No advantage over trazodone IR when used for insommina. No longer available on the market and adolescents. Removed due to lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Not under perview of PMAC not an FDA regulated medication/possible inconsistency in formulations of the same product. No safety-efficacy data for children available. Children and adolescents. Not under perview of PMAC not an FDA regulated medication/possible inconsistency in formulation of the same product. No safety-efficacy
Paliperidone long acting inji Istoperidone long acting inji Istoperidone long acting inji Istoperidone long acting inji Istoperidone Is	4/4/2014 5/11/2015 5/11/2015 Date of Review 3/5/2004 05/01/2015 9/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 10/8/2004, 05/01/2015 10/8/2004 10/8/2004, 05/01/2015 10/8/2004 10/8/2004 10/8/2006 9/4/2009 9/4/2009 9/4/2009 9/4/2009 10/9/2009 10/9/2009 11/5/2010 11/5/2010 11/5/2010 11/5/2010 11/5/2010 11/5/2010 11/5/2011 11/5/2011 11/5/2011 11/5/2011 11/5/2011 11/5/2011 11/5/2011 11/5/2011 11/5/2011 11/5/2011 11/5/2011 11/5/2011 11/5/2011 11/5/2011 11/5/2010	Appi	N N TOVED N N N N N N N N N N N N N N N N N N N	Removed due to lack of data regarding use in children/adolescents. Rationale (additional details available upon request) Risk of liver failure Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profile: EKG changes - OT prolongation. ADR profile: EVG changes - OT prolongation. ADR profile: EVG changes - OT prolongation. ADR profile: EVG changes - OT prolongation. Lack of data re settley and efficacy or in children for psychiatric indications. Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product. Lack of data re efficacy in children for psychiatric indications. Lack of data re efficacy or children for psychiatric indications. ADR profile: EKG changes - OT prolongation. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available feb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available feb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available feb 2010. Removed due to lack of safety data in children. The province of the same product. Lack of safety-efficacy data in children. Data may be available for a province of the same product. No advantage over trazodone IR when used for insommina. No longer available on the market. Removed due to lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. No safety-efficacy data in children. The regulated medication-possible inconsistency in formulations of the same product. No safety-efficacy data or children available. Clinical trials not impressive. Concern over St. buccal dosage form. On approved w
Paliperidone long acting inji Istoperidone long acting inji Istoperidone long acting inji Istoperidone long acting inji Istoperidone Is	4/4/2014 5/1/2015 Date of Review 3/5/2004 5/5/2015 B/5/2004 5/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2009 10/1/2000 11/5/20010 1	Appi	N N TOVED N N N N N N N N N N N N N N N N N N N	Removed: study of 201 children showed no efficacy and significant adverse drug reactions. Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profile: EKG changes - OT protongation. ADR profile: Liver tracity No indication for use as a psychotropic medication in children. Lack of data re stelly and efficacy or in children for psychiatric indications. Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product. Lack of data re efficacy in children for psychiatric indications. Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product. Lack of data re efficacy in children for psychiatric indications. ADR profile: EKG changes - OT protongation. ADR profile: EKG changes - OT protongation. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available Feb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Pending further data once drug is actually available. Lack of safety-efficacy data in children. Data may be available Feb 2010. Removed due to lack of safety data in children. The safety is actually available. No advantage over trazodone IR when used for insommnia. No longer available on the market. Removed due to lack indication for use in children and adolescents. Pending results of clinical trials underway involving children/adolescents. Pending resul
aliperidone long acting inj issperidone long acting inj issperidone long acting inj alepton long alepton long acting inj alepton long acting injuries al	4/4/2014 5/11/2015 5/11/2015 Date of Review 3/5/2004 05/01/2015 9/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 10/8/2004, 05/01/2015 10/8/2004 10/8/2004, 05/01/2015 10/8/2004 10/8/2004 10/8/2006 9/4/2009 9/4/2009 9/4/2009 9/4/2009 10/9/2009 10/9/2009 11/5/2010 11/5/2010 11/5/2010 11/5/2010 11/5/2010 11/5/2010 11/5/2011 11/5/2011 11/5/2011 11/5/2011 11/5/2011 11/5/2011 11/5/2011 11/5/2011 11/5/2011 11/5/2011 11/5/2011 11/5/2011 11/5/2011 11/5/2011 11/5/2010	Appr	N N TOVED N N N N N N N N N N N N N N N N N N N	Removed due to lack of data regarding use in children/adolescents. Rationale (additional details available upon request) Rikk of liver failure Rationale (additional details available upon request) Rikk of liver failure Withdrawn from market ADR profile: EKG changes - OT prolongation. ADR profile: EVG changes - OT prolongation. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available Feb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Pending further data noned rulp is actually available of the prolongation. Only 1 Illy sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available. No advantage over trazodone IR when used for insommina. No longer available on the market. Removed due to lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Pending results of clinical trials underway involving children/adolescents. No safety-efficacy data or children available. Clinical tri
Paliperidone long acting inj Isteperidone Ist	4/4/2014 5/1/2015 Date of Review 3/5/2004 5/5/2015 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2008 9/4/2009 9/4/2009 9/4/2009 9/4/2009 10/9/2009 9/4/2009 10/9/2009 10/9/2009 11/5/2010 5/7/2010 8/6/2010 11/5/2010 11/7/2011 11/7/2011 11/7/2011 11/7/2011 11/7/2011 11/7/2011 11/7/2011 11/7/2011 11/7/2011 11/7/2011 11/7/2011 11/7/2011 11/5/2010 11/5/2010 15/5/2010 8/5/2010 8/5/2010 8/5/2010 8/5/2010 9/5/2001 8/5/2010 9/5/2010 8/5/2010 9/5/2010	Appr	N N TOVED N N N N N N N N N N N N N N N N N N N	Removed: study of 201 children showed no efficacy and significant adverse drug reactions. Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profile: EKG changes - OT protongation. ADR profile: Liver troxicity. No indication for use as a psychotropic medication in children. Lack of data re stelly and efficacy or in children for psychiatric indications. Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product. Lack of data re efficacy in children for psychiatric indications. ADR profile: EKG changes - OT protongation. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available Feb 201 0. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available feb 201 0. Removed due to lack of safety data in children. Data may be available feb 201 0. Removed due to lack of safety data in children. Data may lack of the careful thration is a concern. OTC interval is a concern. Only 1 Lilly soponered study completed. Additional studies in pipeline. Deny approval until efficacy data is available. No advantage over trazodone IR when used for insommnia. No longer available on the market. Removed due to lack indication for use in children and adolescents. Pending results of clinical trials underway involving children/adolescents. Pending results
Paliperdone long acting inj Istoperione long Istoperi	4/4/2014 5/11/2015 5/11/2015 5/11/2015 5/11/2015 5/11/2015 5/11/2015 5/11/2015 5/11/2015 5/11/2015 5/11/2015 5/11/2015 5/11/2004 5/11/2004 5/11/2004 5/11/2004 5/11/2006 5/11/2001	Appr	N N TOVED N N N N N N N N N N N N N N N N N N N	Removed: study of 201 children showed no efficacy and significant adverse drug reactions. Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profile: EKG changes - OT protongation. ADR profile: Liver troxicity. No indication for use as a psychotropic medication in children. Lack of data re stelly and efficacy or in children for psychiatric indications. Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product. Lack of data re efficacy in children for psychiatric indications. ADR profile: EKG changes - OT protongation. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available Feb 201 0. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available feb 201 0. Removed due to lack of safety data in children. Data may be available feb 201 0. Removed due to lack of safety data in children. Data may lack of the careful thration is a concern. OTC interval is a concern. Only 1 Lilly soponered study completed. Additional studies in pipeline. Deny approval until efficacy data is available. No advantage over trazodone IR when used for insommnia. No longer available on the market. Removed due to lack indication for use in children and adolescents. Pending results of clinical trials underway involving children/adolescents. Pending results
aliperidone long acting inj issperidone is	4/4/2014 5/1/2015 Date of Review 3/5/2004 5/5/2015 B/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 8/5/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2004 10/8/2009 9/4/2009 9/4/2009 9/4/2009 9/4/2009 10/9/2009 9/4/2009 10/9/2009 11/5/2010 5/7/2010 5/7/2010 8/6/2010 11/5/2010 11/7/2011 11/7/2011 11/7/2011 11/7/2011 11/7/2011 5/7/2010 8/5/2010 9/5/2000 9/5/	App	N TOVED N N N N N N N N N N N N N	Removed: study of 201 children showed no efficacy and significant adverse drug reactions. Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profile: EKG changes - OT protongation. ADR profile: Liver twoicity. No indication for use as a psychotropic medication in children. Lack of data re stelly and efficacy or in children for psychiatric indications. Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product. Lack of data re efficacy in children for psychiatric indications. Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product. Lack of data re efficacy in children for psychiatric indications. ADR profile: EKG changes - OT protongation. ADR profile: EKG changes - OT protongation. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available Feb 201 0. Removed due to lack of safety data and experience with use in children and adolescents. Pending further data once drug is actually available. Lack of safety-efficacy data in children. Data may be available feb 201 0. Removed due to lack of safety data in children. The train profits is unique to the control of the same product. No advantage over trazodone IR when used for insommnia. No longer available on the market. Removed due to lack indication for use in children and adolescents. Pending results of clinical trials underway involving children/adolescents. Pending results of clinical trials underway involving
aliperidone long acting inj issperidone long issperidone i	4/4/2014 5/11/2015 5/11/2015 5/11/2015 5/11/2015 5/11/2015 5/11/2015 5/11/2015 5/11/2015 5/11/2015 5/11/2015 5/11/2016 5/11/2004 5/11/2004 5/11/2004 5/11/2004 5/11/2006 5/11/2001 5/11/20	App	N TOVED N N N N N N N N N N N N N	Removed due to lack of data regarding use in children/adolescents. Removed: study of 201 children showed no efficacy and significant adverse drug reactions. Rationale (additional details available upon request) Risk of liver failure Withdrawn from market ADR profile: EKG changes - OT prolongation. ADR profile: EVE trotxicity. No indication for use as a psychotropic medication in children. Lack of data re settley and efficacy or in children for psychiatric indications. Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product. Lack of data re efficacy in children for psychiatric indications. ADR profile: EKG changes - OT prolongation. ADR profile: EKG changes - OT prolongation. ADR profile: EKG changes - OT prolongation. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available Feb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available Feb 2010. Removed due to lack of safety data and experience with use in children and adolescents. Lack of safety-efficacy data in children. Data may be available. Peb 2010. Removed due to lack of safety data in children. Tails not impressive. Need for careful thration is a concern. OTC interval is a concern. Only 1 tilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available. No advantage over trazodone IR when used for insommina. No longer available on the market. Removed due to lack indication for use in children and adolescents. Removed due to lack indication for use in children and adolescents. Pending results of clinical trials underway involving children/adolescents. Pending results of clinical trials underway involving children/adolescents. No safety-efficacy data for children available. Clinical trials not impressive. Concern over St